Brentuximab Beats Standard Therapies for CTCL
Copyright policy )Brentuximab Beats Standard Therapies for CTCL
Abstract Compared with a physician's choice of either methotrexate or bexarotene, the CD30-directed antibody–drug conjugate brentuximab vedotin led to significantly superior clinical responses in patients with cutaneous T-cell lymphomas, according to the results of the international phase III ALCANZA trial.
Brentuximab Vedotin, Immunoconjugates, Treatment Outcome, Clinical Trials, Phase III as Topic, Humans, Ki-1 Antigen, Peripheral Nervous System Diseases, Disease-Free Survival, Lymphoma, T-Cell, Cutaneous, Randomized Controlled Trials as Topic
Brentuximab Vedotin, Immunoconjugates, Treatment Outcome, Clinical Trials, Phase III as Topic, Humans, Ki-1 Antigen, Peripheral Nervous System Diseases, Disease-Free Survival, Lymphoma, T-Cell, Cutaneous, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!